BE1004932A3 - Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales. - Google Patents

Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales. Download PDF

Info

Publication number: BE1004932A3
Authority: BE; Belgium
Prior art keywords: group; general formula; gnrh; tumors; hormone
Prior art date: 1988-05-10

Application number

BE8900499A

Other languages

English (en)

French (fr)

Inventor

Gyoergy Keri

Robert I Nicholson

Istvan Teplan

Tamas Gulyas

Aniko Horvath

Gyoergyi Boekoenyi

Balazs Szoeke

Agnes Balogh

Orsolya Csuka

Original Assignee

Innofinance Altalanos Innovaci

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-05-10

Filing date

1989-05-10

Publication date

1993-03-02

1989-05-10 Application filed by Innofinance Altalanos Innovaci filed Critical Innofinance Altalanos Innovaci

1993-03-02 Application granted granted Critical

1993-03-02 Publication of BE1004932A3 publication Critical patent/BE1004932A3/fr

Links

102000006771 Gonadotropins Human genes 0.000 title description 7
108010086677 Gonadotropins Proteins 0.000 title description 7
230000000259 anti-tumor effect Effects 0.000 title description 7
239000002622 gonadotropin Substances 0.000 title description 7
206010028980 Neoplasm Diseases 0.000 claims abstract description 29
229940088597 hormone Drugs 0.000 claims abstract description 22
239000005556 hormone Substances 0.000 claims abstract description 22
238000000034 method Methods 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
230000001419 dependent effect Effects 0.000 claims abstract description 15
108050000048 Gonadoliberin Proteins 0.000 claims abstract description 9
102000009165 Gonadoliberin Human genes 0.000 claims abstract description 9
230000008569 process Effects 0.000 claims abstract description 9
150000001875 compounds Chemical class 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims abstract description 7
150000003839 salts Chemical class 0.000 claims abstract description 7
230000003054 hormonal effect Effects 0.000 claims abstract description 6
230000001939 inductive effect Effects 0.000 claims abstract description 6
239000002253 acid Substances 0.000 claims abstract description 5
239000002184 metal Substances 0.000 claims abstract description 4
229910052751 metal Inorganic materials 0.000 claims abstract description 4
150000007513 acids Chemical class 0.000 claims abstract description 3
239000000654 additive Substances 0.000 claims abstract description 3
239000000969 carrier Substances 0.000 claims abstract description 3
150000004696 coordination complex Chemical class 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 5
150000008575 L-amino acids Chemical group 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
150000008574 D-amino acids Chemical group 0.000 claims description 2
125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims description 2
125000003368 amide group Chemical group 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
125000003827 glycol group Chemical group 0.000 claims description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
125000001982 tryptophyl group Chemical group 0.000 claims description 2
-1 alkanoyl amide Chemical class 0.000 claims 1
125000001998 leucyl group Chemical group 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000002434 gonadorelin derivative Substances 0.000 abstract 1
238000011282 treatment Methods 0.000 description 20
102000009151 Luteinizing Hormone Human genes 0.000 description 16
108010073521 Luteinizing Hormone Proteins 0.000 description 16
229940040129 luteinizing hormone Drugs 0.000 description 16
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 14
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 14
230000000694 effects Effects 0.000 description 14
229940028334 follicle stimulating hormone Drugs 0.000 description 14
210000004027 cell Anatomy 0.000 description 12
206010006187 Breast cancer Diseases 0.000 description 10
208000026310 Breast neoplasm Diseases 0.000 description 10
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 10
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 10
230000006870 function Effects 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 9
230000002611 ovarian Effects 0.000 description 9
230000016087 ovulation Effects 0.000 description 9
230000007423 decrease Effects 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
230000010534 mechanism of action Effects 0.000 description 8
210000001672 ovary Anatomy 0.000 description 8
241000124008 Mammalia Species 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
241000251468 Actinopterygii Species 0.000 description 6
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
238000000586 desensitisation Methods 0.000 description 6
235000019688 fish Nutrition 0.000 description 6
230000002710 gonadal effect Effects 0.000 description 6
229940094892 gonadotropins Drugs 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
150000003431 steroids Chemical class 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
230000004614 tumor growth Effects 0.000 description 6
WPKQYFUSPONRAT-BXXNOCLASA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-5-amino-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hy Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 WPKQYFUSPONRAT-BXXNOCLASA-N 0.000 description 5
ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 5
206010062767 Hypophysitis Diseases 0.000 description 5
230000003325 follicular Effects 0.000 description 5
230000035800 maturation Effects 0.000 description 5
210000003635 pituitary gland Anatomy 0.000 description 5
229960003387 progesterone Drugs 0.000 description 5
239000000186 progesterone Substances 0.000 description 5
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
229960005309 estradiol Drugs 0.000 description 4
229930182833 estradiol Natural products 0.000 description 4
210000002149 gonad Anatomy 0.000 description 4
230000001817 pituitary effect Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
NMJREATYWWNIKX-XJIZABAQSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 NMJREATYWWNIKX-XJIZABAQSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000001850 reproductive effect Effects 0.000 description 3
241000894007 species Species 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
229960003604 testosterone Drugs 0.000 description 3
241000972773 Aulopiformes Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
101000708425 Homo sapiens Syntaphilin Proteins 0.000 description 2
102100033467 L-selectin Human genes 0.000 description 2
102100032836 Syntaphilin Human genes 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000011278 mitosis Effects 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
230000021595 spermatogenesis Effects 0.000 description 2
239000003270 steroid hormone Substances 0.000 description 2
230000010009 steroidogenesis Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
206010060999 Benign neoplasm Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 1
125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
101150111020 GLUL gene Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
102000008238 LHRH Receptors Human genes 0.000 description 1
108010021290 LHRH Receptors Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000005002 female reproductive tract Anatomy 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
101150108262 gnrh1 gene Proteins 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
XCUBVSAYUSFHNN-UHFFFAOYSA-N hydron;(2-nitrophenyl)hydrazine;chloride Chemical class [Cl-].[NH3+]NC1=CC=CC=C1[N+]([O-])=O XCUBVSAYUSFHNN-UHFFFAOYSA-N 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000029849 luteinization Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
230000021121 meiosis Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
210000002394 ovarian follicle Anatomy 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000004800 psychological effect Effects 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
208000012201 sexual and gender identity disease Diseases 0.000 description 1
208000015891 sexual disease Diseases 0.000 description 1
230000035938 sexual maturation Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)

BE8900499A 1988-05-10 1989-05-10 Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales. BE1004932A3 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU882347A HU199694B (en)	1988-05-10	1988-05-10	Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives

Publications (1)

Publication Number	Publication Date
BE1004932A3 true BE1004932A3 (fr)	1993-03-02

Family

ID=10958948

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE8900499A BE1004932A3 (fr)	1988-05-10	1989-05-10	Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales.

Country Status (16)

Country	Link
JP (1)	JPH0215097A (de)
KR (1)	KR900017610A (de)
BE (1)	BE1004932A3 (de)
CH (1)	CH678013A5 (de)
DE (1)	DE3915317A1 (de)
DK (1)	DK228289A (de)
FI (1)	FI892275A7 (de)
FR (1)	FR2631237A1 (de)
GB (1)	GB2218335B (de)
GR (1)	GR890100315A (de)
HU (1)	HU199694B (de)
IL (1)	IL89998A0 (de)
IT (1)	IT1229251B (de)
LU (1)	LU87516A1 (de)
NL (1)	NL8901159A (de)
SE (1)	SE8901660L (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5760000A (en) *	1994-05-13	1998-06-02	University Technologies International,Inc.	Inhibition of liver cancer by the use of GnRH and GnRH analogs
US6054432A (en) *	1996-09-12	2000-04-25	Asta Medica Aktiengesellschaft	Means for treating prostate hypertrophy and prostate cancer

Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4410514A (en) *	1982-12-06	1983-10-18	The Salk Institute For Biological Studies	GnRH Agonists
FR2556970A1 (fr) *	1983-12-23	1985-06-28	Koezponti Valto Hitelbank	Procede d'obtention de produits sexuels prets a la fecondation a partir de poissons sexuellement matures
GB2152059A (en) *	1983-12-23	1985-07-31	Koezponti Valto Hitelbank	Gonadoliberin derivatives
WO1986001105A1 (en) *	1984-08-02	1986-02-27	Fernand Labrie	Pharmaceutical composition for combination therapy of hormone dependent cancers
GB2179250A (en) *	1985-07-18	1987-03-04	Innofinance Altalanos Innovaci	Process for obtaining sexual products from mammals
GB2185025A (en) *	1986-01-03	1987-07-08	Innofinance Altalanos Innovaci	Gonadoliberin derivatives containing an aromatic aminocarboxylic acid in the 6-position, pharmaceutical and veterinary compositions containing them and process for preparing same
US4721775A (en) *	1985-08-26	1988-01-26	Board Of Regents, The University Of Texas System	Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
US4760053A (en) *	1984-08-02	1988-07-26	Fernand Labrie	Combination therapy for selected sex steroid dependent cancers

1988
- 1988-05-10 HU HU882347A patent/HU199694B/hu active IP Right Revival
1989
- 1989-04-18 IL IL89998A patent/IL89998A0/xx unknown
- 1989-05-08 CH CH1725/89A patent/CH678013A5/de not_active IP Right Cessation
- 1989-05-09 NL NL8901159A patent/NL8901159A/nl not_active Application Discontinuation
- 1989-05-10 JP JP1115265A patent/JPH0215097A/ja active Pending
- 1989-05-10 KR KR1019890006230A patent/KR900017610A/ko not_active Withdrawn
- 1989-05-10 GR GR890100315A patent/GR890100315A/el unknown
- 1989-05-10 SE SE8901660A patent/SE8901660L/ not_active Application Discontinuation
- 1989-05-10 DK DK228289A patent/DK228289A/da not_active Application Discontinuation
- 1989-05-10 BE BE8900499A patent/BE1004932A3/fr not_active IP Right Cessation
- 1989-05-10 GB GB8910724A patent/GB2218335B/en not_active Expired - Fee Related
- 1989-05-10 LU LU87516A patent/LU87516A1/fr unknown
- 1989-05-10 FI FI892275A patent/FI892275A7/fi not_active Application Discontinuation
- 1989-05-10 DE DE3915317A patent/DE3915317A1/de not_active Withdrawn
- 1989-05-10 FR FR8906094A patent/FR2631237A1/fr active Pending
- 1989-05-11 IT IT8920435A patent/IT1229251B/it active

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4410514A (en) *	1982-12-06	1983-10-18	The Salk Institute For Biological Studies	GnRH Agonists
FR2556970A1 (fr) *	1983-12-23	1985-06-28	Koezponti Valto Hitelbank	Procede d'obtention de produits sexuels prets a la fecondation a partir de poissons sexuellement matures
GB2152059A (en) *	1983-12-23	1985-07-31	Koezponti Valto Hitelbank	Gonadoliberin derivatives
WO1986001105A1 (en) *	1984-08-02	1986-02-27	Fernand Labrie	Pharmaceutical composition for combination therapy of hormone dependent cancers
US4760053A (en) *	1984-08-02	1988-07-26	Fernand Labrie	Combination therapy for selected sex steroid dependent cancers
GB2179250A (en) *	1985-07-18	1987-03-04	Innofinance Altalanos Innovaci	Process for obtaining sexual products from mammals
US4721775A (en) *	1985-08-26	1988-01-26	Board Of Regents, The University Of Texas System	Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
GB2185025A (en) *	1986-01-03	1987-07-08	Innofinance Altalanos Innovaci	Gonadoliberin derivatives containing an aromatic aminocarboxylic acid in the 6-position, pharmaceutical and veterinary compositions containing them and process for preparing same

Also Published As

Publication number	Publication date
DK228289A (da)	1989-11-11
GB2218335B (en)	1991-09-25
NL8901159A (nl)	1989-12-01
FI892275A0 (fi)	1989-05-10
CH678013A5 (de)	1991-07-31
KR900017610A (ko)	1990-12-19
DE3915317A1 (de)	1989-11-23
IL89998A0 (en)	1989-12-15
JPH0215097A (ja)	1990-01-18
SE8901660L (sv)	1989-11-11
IT8920435A0 (it)	1989-05-11
LU87516A1 (fr)	1990-12-11
HUT49813A (en)	1989-11-28
HU199694B (en)	1990-03-28
IT1229251B (it)	1991-07-26
GB8910724D0 (en)	1989-06-28
DK228289D0 (da)	1989-05-10
SE8901660D0 (sv)	1989-05-10
GR890100315A (el)	1990-03-12
FR2631237A1 (fr)	1989-11-17
FI892275A7 (fi)	1989-11-11
GB2218335A (en)	1989-11-15

Legal Events

Date

Code

Title

Description

1994-11-30

RE

Patent lapsed

Owner name: INNOFINANCE ALTALANOS INNOVACIOS PENZINTEZET

Effective date: 19940531

Publication	Publication Date	Title
Breton et al.	1998	GTH I and GTH II secretion profiles during the reproductive cycle in female rainbow trout: relationship with pituitary responsiveness to GnRH-A stimulation
Greenstein et al.	1987	Regeneration of the thymus in old male rats treated with a stable analogue of LHRH
De Leeuw et al.	1985	Pimozide modulates the luteinizing hormone-releasing hormone effect on gonadotrophin release in the African catfish, Clarias lazera
De Leeuw et al.	1987	The regulation of gonadotropin release by neurohormones and gonadal steroids in the African catfish, Clarias gariepinus
Sower	2003	The endocrinology of reproduction in lampreys and applications for male lamprey sterilization
BG61637B1 (bg)	1998-02-27	Състав за трансдермално приложение,съдържащ селегилин,и метод за получаването му
Tannenbaum et al.	1992	Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin.
Meijs-Roelofs et al.	1979	Maturation of the inhibitory feedback action of oestrogen on follicle-stimulating hormone secretion in the immature female rat: a role for alpha-foetoprotein
Tsafriri et al.	1976	Capacity of immunologically purified FSH to stimulate cyclic AMP accumulation and steroidogenesis in Graafian follicles and to induce ovum maturation and ovulation in the rat
Sandow et al.	1980	Hypothalamic-pituitary-testicular function in rats after supraphysiological doses of a highly active LRH analogue (buserelin)
Licht et al.	1968	Somatotropic effects of exogenous prolactin and growth hormone in juvenile lizards (Lacerta s. sicula)
Moszkowska et al.	1971	The influence of the pineal body on the gonadotropic function of the hypophysis
BE1004932A3 (fr)	1993-03-02	Utilisation de derives de la gonadoliberine pour preparer des compositions pharmaceutiques anti-tumorales.
IE56483B1 (en)	1991-08-14	Lhrh preparations for intranasal administration
Ahluwalia et al.	1970	Effects of exogenous hormones on the male reproductive organs of vitamin A-deficient rats
HU189394B (en)	1986-06-30	Method for producing spermatozoa suitable for fertilization from mature fishes
FR3082842A1 (fr)	2019-12-27	Polymorphe de cis-clomiphene (zuclomiphene) et procedes d'utilisation de celui-ci
ADAMS et al.	1986	Suppression of Plasma Gonadotropins and Testosterone in Adult Male Monke (Macaca fascicularis) by a Potent Inhibitory Analog of Gonadotropin-Releasing Hormone
Holloway et al.	1997	The Effects ofN-Methyl-d, l-aspartate and Gonadotropin-Releasing Hormone onin VitroGrowth Hormone Release in Steroid-Primed Immature Rainbow Trout, Oncorhynchus mykiss
Carolsfeld et al.	1988	Induced sexual maturation of herring using GnRH ‘quick-release’cholesterol pellets
Bellido et al.	1990	Possible role of changes in post-natal gonadotrophin concentrations on permanent impairment of the reproductive system in neonatally oestrogenized male rats
Garcia	1990	Advancement of sexual maturation and spawning of sea bass, Lates calcarifer (Bloch), using pelleted luteinizing hormone-releasing hormone analogue and 17α-methyltestosterone
US4381298A (en)	1983-04-26	Oral male contraceptive composition
Clementi et al.	1969	Influence of pineal gland principles on gonadotrophin-producing cells of the rat anterior pituitary gland: an electron microscopic study
DAHL et al.	1974	The ultrastructure of the accessory sex organs of the male rat: the effect of cyproterone acetate